Clinical Trend of the Week (December 5-11): Portrazza
Once again, the approval of a promising new drug resulted in the top search term of the week. Necitumumab (Portrazza®) was approved by the US Food and Drug Administration to be used in combination with two forms of chemotherapy: gemcitabine and cisplatin. Patients with metastatic squamous non-small cell lung cancer (NSCLC) who have not previously been treated can now use this combination therapy. In the SQUIRE trial, median overall survival improved by 1.6 months when necitumumab was included in the treatment regimen with the other chemotherapy drugs. Considering that the 5-year survival rate is less than 5% for this condition, clinicians are no doubt eager for any treatment option that may provide patients more time.
For more in-depth clinical information, see Non–Small Cell Lung Cancer.
Medscape © 2016
WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ryan Syrek. Clinical Trends for December 2015 - Medscape - Jan 01, 2016.
Comments